HSBC Holdings’s Stemline Therapeutics, Inc. STML Stock Holding History

HSBC Holdings’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-21,613	Closed	-$105K	–	2950
2020 Q1	$105K	Buy	21,613 +8,746	+68%	+$56.7K	﹤0.01%	2469
2019 Q4	$137K	Sell	12,867 -9,021	-41%	-$89.6K	﹤0.01%	2893
2019 Q3	$228K	Buy	+21,888	New	+$286K	﹤0.01%	2797

HSBC Holdings's STML Position: Q2 2020 in Review

HSBC Holdings sold out of Stemline Therapeutics, Inc. (STML) in Q2 2020, closing a stake of 21,613 shares — an estimated $105K sold.

HSBC Holdings first reported a position in STML in Q3 2019 and held it in 3 quarters. The position peaked at $228K in Q3 2019. 0 funds tracked by Wall St. Rank hold STML as of Q2 2020.

HSBC Holdings reported no remaining Stemline Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
HSBC Holdings sold 21,613 Stemline Therapeutics, Inc. shares in Q2 2020, an estimated $105K.
HSBC Holdings first reported a position in Stemline Therapeutics, Inc. in Q3 2019 and held it in 3 quarters.
HSBC Holdings's Stemline Therapeutics, Inc. position peaked at $228K in Q3 2019.
0 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2020.

Based on HSBC Holdings's 13F filing for Q2 2020, filed 14 Aug 2020.